{"denoms":[{"counts":[{"groupId":"BG000","value":"31"}],"units":"Participants"}],"groups":[{"description":"Patients receive gemcitabine hydrochloride IV over 30 minutes on day 1 and cisplatin IV on day 1 or divided over days 1 and 2. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-8 weeks after chemotherapy, patients undergo radical cystectomy.\n\ngemcitabine hydrochloride: Given IV\n\ncisplatin: Given IV\n\ntherapeutic conventional surgery: Undergo radical cystectomy\n\nlaboratory biomarker analysis: Correlative studies","id":"BG000","title":"Treatment (Gemcitabine Hydrochloride, Cisplatin, Surgery)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"51","upperLimit":"82","value":"69"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"21"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}],"title":"T2N0M0"},{"measurements":[{"groupId":"BG000","value":"15"}],"title":"T3N0M0"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"T4aN0Mo/TxN1M0"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Baseline clinical stage","unitOfMeasure":"Participants"}],"populationDescription":"The tumor in patients was graded by TNM staging where T refers to the stage of primary tumor, n refers to the regional lymph nodes, M refers to distant metastasis. T0 - no evidence of primary tumor; N0- no regional lymph nodes; M0-no distant metastasis"}